Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20969085 | 1.00 | CA1 (0.39) | CA1CA2CA4KMT2ANOS1 | |
| SCHEMBL15463086 | 1.00 | CA1 (0.39) | CA1CA2CA4KMT2ANOS1 | |
| SCHEMBL3427906 | 0.85 | KMT2A (0.34) | CA1CA2CA4KMT2AMEN1 | |
| SCHEMBL22862061 | 0.84 | CA1 (0.37) | CA1CA2CA4KMT2ANOS1 | |
| SCHEMBL9409590 | 0.82 | CA1 (0.34) | CA1CA2CA4KMT2A | |
| SCHEMBL20969056 | 0.82 | CA1 (0.30) | CA1 | |
| SCHEMBL20969082 | 0.80 | CA1 (0.33) | CA1CA2CA4KMT2ATLR4 | |
| SCHEMBL15463085 | 0.79 | CA1 (0.41) | CA1CA2CA4KMT2ANOS1 | |
| SCHEMBL29361207 | 0.79 | — | — | |
| SCHEMBL13497137 | 0.74 | MEN1 (0.35) | KMT2AMEN1TLR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | NORTHWESTERN UNIVERSITY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | MYC, CDK4, CDKL3 | CA1 1225/4885CA2 1542/4885CA4 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.